GenIP Plc (GNIP) Passes All Nine AGM Resolutions with Strong Shareholder Support

All Nine Resolutions Passed at GenIP's 2026 Annual General Meeting

GenIP Plc confirmed via a Regulatory News Service announcement published on 24 June 2026 that every resolution put to shareholders at its Annual General Meeting had been duly passed. Nine resolutions in total were proposed, spanning routine governance matters such as the approval of the Annual Report and Accounts, through to the re-election of individual directors and the grant of share allotment and pre-emption disapplication authorities. The Company described the outcome as pleasing, consistent with the positive framing contained within the announcement.

The AGM result represents a routine but important governance milestone for an AIM-quoted company at a relatively early stage of its development. For GenIP, which only recently established its dual-service commercial model combining Invention Intelligence products with IP Commercialisation Services, securing a clear Shareholder mandate for its board and Capital-structure/">Capital Structure provides a degree of operational stability as management pursues its stated strategic goals. The full text of the resolutions is available on the Company's website at genip.ai, as noted in the disclosure.

Annual Report, Accounts and Auditor Appointment Receive Near-Unanimous Backing

Resolution 1, seeking shareholder approval for the Annual Report and Accounts, attracted the highest level of support of any resolution on the agenda. The announcement states that 13,034,359 votes were cast in favour, representing 99.95% of votes validly cast, with only 6,657 votes against and 1,000 votes withheld. The total number of votes cast on this resolution was 13,041,016. This near-unanimous endorsement of GenIP's financial reporting suggests shareholders are broadly content with the standard and transparency of the Company's disclosures.

Resolution 2, which sought to re-appoint HW Fisher LLP as auditor of the Company, was passed with 13,013,071 votes in favour, equating to 99.79% of votes validly cast. Against votes totalled 27,945, representing 0.21% of the votes cast, with 1,000 votes withheld. Resolution 3, authorising the directors to determine the auditor's remuneration, also passed comfortably, with 12,884,866 votes in favour at 98.8% and 156,150 against at 1.2%. The continued appointment of HW Fisher LLP provides consistency in the Company's audit arrangements, which investors in smaller AIM-listed companies often regard as an important governance consideration.

Board Composition Confirmed as All Four Directors Successfully Re-elected

Four director re-election resolutions were put before shareholders, covering Lord David Willetts, Melissa Cruz, Kevin Fitzpatrick, and Professor David Gann CBE. All four were returned to the board, though the voting patterns differed marginally depending on the individual. Lord David Willetts (Resolution 4) was re-elected with 12,634,053 votes in favour, equating to 97.23% of votes cast, and 359,960 votes against at 2.77%. Notably, 48,003 votes were withheld on this resolution, meaning total votes cast for the purpose of calculating percentages were 12,994,013 rather than the full 13,041,016.

Melissa Cruz, who serves as Chief Executive Officer of the Company, was re-elected under Resolution 5 with 12,706,872 votes in favour, representing 97.79% of votes cast, and 287,141 against at 2.21%. Professor David Gann CBE received the same vote split as Melissa Cruz — 12,706,872 in favour at 97.79% and 287,141 against at 2.21% under Resolution 7. Kevin Fitzpatrick mirrored Lord Willetts with 12,634,053 votes in favour at 97.23% and 359,960 against at 2.77% under Resolution 6. All four resolutions saw 48,003 votes withheld. The re-election of all directors ensures continuity of Leadership as GenIP pursues its ambitions in the generative AI analytics market.

Shareholder Participation Rate in Context of 25.5 Million Shares in Issue

As at 24 June 2026, the announcement discloses that there were 25,517,461 ordinary shares in issue, with shareholders entitled to one vote per share. The total votes cast across the majority of resolutions were approximately 13,041,016, indicating that roughly 51% of the total shares in issue were represented at the AGM either in person or by proxy. This level of participation is a useful reference point when assessing the degree to which the board's mandate reflects the broader shareholder base.

It should be noted, as the announcement clearly states, that votes withheld are not votes in law and have not been included in the calculation of the proportion of votes for and against any resolution. Proxy appointments which gave discretion to the Chairman of the AGM were included within the "For" total for the relevant resolutions. These technical voting conventions are standard practice under UK company law and the AIM Rules, and their correct application here is consistent with proper governance administration.

Share Allotment Authority and Pre-emption Disapplication Approved by Shareholders

Two capital-related resolutions were also put to and passed by shareholders. Resolution 8 authorised the directors to allot shares up to an aggregate nominal amount equal to £54,224.60. This resolution was approved with 12,634,105 votes in favour, representing 96.89% of votes cast, and 405,908 against at 3.11%, with 2,003 votes withheld. Resolution 9 authorised the directors to disapply pre-emption rights in respect of a rights issue and otherwise up to the same aggregate nominal amount of £54,224.60, and attracted an identical vote: 12,634,105 in favour at 96.89% and 405,908 against at 3.11%.

The disapplication of pre-emption rights, even where approved, is a resolution that investors in smaller growth companies often scrutinise carefully. In this instance, the 3.11% of votes cast against each of Resolutions 8 and 9 indicates that a minority of shareholders expressed some reservation, though the resolutions passed comfortably. The aggregate nominal amount of £54,224.60 relates to the Company's Share Capital structure; the actual number of shares this represents will depend on the nominal value per share, which the announcement does not separately itemise. The company did not disclose the precise number of new shares this authority would permit in the announcement itself, though investors can cross-reference the Notice of AGM on the Company's website for the full resolution text.

GenIP's Dual-Service Model Underpins the Commercial Case Shareholders Are Backing

The AGM result must be read in the context of what GenIP does as a Business. The Company operates two service lines: the Invention Intelligence Product Suite, which delivers AI-powered market intelligence reports assessing the commercial potential of emerging technologies, and IP Commercialisation Services, which provides end-to-end engagement support to help research organisations bring innovations to market. Together, the announcement describes these as forming a unified GenAI-enabled platform for innovation triage and execution.

The Company's stated value proposition is that its proprietary generative AI algorithms, combined with expert human analysis, deliver what it terms "decision-grade insights and talent solutions" to corporates, venture funds, and research institutions. This positioning at what the Company describes as "the intersection of generative AI and innovation strategy" places it within one of the most actively discussed segments of the technology market. Investors backing GenIP at the AGM will be conscious that the Company's commercial traction and Revenue progression will ultimately validate or challenge this positioning. The company did not disclose revenue figures or trading updates within this announcement.

Three-Pillar Growth Strategy Shapes the Outlook for GNIP Shareholders

GenIP has publicly articulated a three-pillar growth strategy: organic expansion, service deepening, and strategic acquisitions. Under organic expansion, the Company intends to scale its Invention Evaluator and Recruitment Services through targeted outreach to corporates, Venture Capital firms, and research institutions. Under service deepening, the strategy involves enhancing functionality and Margin by expanding generative AI capabilities across both existing service lines to unlock new use cases and customer segments.

The third pillar — strategic acquisitions — involves pursuing bolt-on acquisitions of complementary generative AI services with what the Company describes as "validated market traction" in order to broaden its offering and accelerate growth. The shareholder approval of the share allotment and pre-emption disapplication authorities under Resolutions 8 and 9 is potentially relevant in this context, as such authorities are commonly used by AIM companies to facilitate future fundraisings or consideration share issuances linked to acquisitions. Investors may be watching closely to see whether management deploys these authorities in the near term in pursuit of its stated Acquisition strategy.

Nominated Adviser, Brokers and Financial PR Advisers Supporting the AIM-Listed Company

GenIP's adviser and communications structure reflects its status as a quoted AIM company with active Capital Markets relationships. Beaumont Cornish Limited acts as the Company's Nominated Adviser, with Roland Cornish, Asia Szusciak, and Andrew Price named as the relevant contacts. The announcement notes, in standard regulatory language, that Beaumont Cornish's responsibilities as Nominated Adviser are owed solely to the London Stock Exchange, and that Beaumont Cornish is not acting for and will not be responsible to any other persons for the protections afforded to its customers.

AlbR Capital Limited acts as broker, with Colin Rowbury and Jon Belliss named as the relevant individuals, whilst CMC Markets serves as joint broker via Douglas Crippen. Redchurch Communications provides financial Public Relations support, with John Casey named as the media contact. Chief Executive Officer Melissa Cruz is listed as the Company contact, reachable via Redchurch Communications. This advisory infrastructure is broadly consistent with what investors would expect for an AIM-quoted technology company of GenIP's size and stage of development.

What the AGM Voting Data Reveals About Institutional and Retail Investor Sentiment

Analysing the voting data disclosed in the announcement offers some indirect insight into shareholder composition and sentiment, though it should be noted that any such analysis is inferential. Across resolutions where no votes were withheld, total votes cast were consistently 13,041,016 out of 25,517,461 shares in issue, implying that the shareholders who participated accounted for slightly more than half of the total voting capital. This level of engagement is neither unusually high nor low for an AIM-quoted company where a portion of the free float may be held by retail investors who do not routinely exercise voting rights.

The marginal differences in the voting patterns between director re-elections — with Lord Willetts and Kevin Fitzpatrick each attracting slightly more against votes than Melissa Cruz and Professor David Gann CBE — are not, on the face of the announcement, indicative of any specific shareholder concerns that the Company has chosen to address publicly. The 48,003 votes withheld on all four director re-election resolutions appear consistent, suggesting a specific block of shareholders applied the same position uniformly across all board appointments. The immediate share price impact was not clear from available public information.

Governance Standards and AIM Compliance Reflected in Detailed Vote Disclosure

The level of granularity provided in GenIP's AGM result announcement — including individual vote counts for and against, percentages of votes cast, and withheld vote totals for every resolution — is consistent with best practice for AIM-listed companies and with the requirements of the UK Corporate Governance Code's principles around shareholder engagement and transparency. Publishing a detailed breakdown of all nine resolutions, rather than simply stating that all resolutions were passed, provides shareholders and the wider market with the information necessary to assess where divergences of view may exist.

For a company of GenIP's scale and stage, maintaining rigorous governance standards is an important signal to institutional and professional investors who may be assessing the Company as a potential portfolio addition. The timely disclosure of the AGM result via the Regulatory News Service on the same day as the meeting itself also reflects compliance with the AIM Rules for Companies regarding timely dissemination of price-sensitive and material information. Investors considering GNIP should conduct their own Due Diligence and take independent financial advice where appropriate, as forward-looking statements within the announcement are subject to risks and uncertainties that could cause actual outcomes to differ materially from those described.